Endothelin receptor subtypes in human and guinea‐pig pulmonary tissues

1 In this study the endothelin (ET) receptor subtypes mediating contractions produced by ET‐1 in human and guinea‐pig pulmonary tissues were investigated. In addition the receptor responsible for ET‐1‐induced prostanoid release in human bronchus was determined. 2 In human bronchus and human pulmonar...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:British journal of pharmacology 1993-11, Vol.110 (3), p.1175-1183
Hauptverfasser: Hay, D.W.P., Luttmann, M.A., Hubbard, W.C., Undem, B.J.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:1 In this study the endothelin (ET) receptor subtypes mediating contractions produced by ET‐1 in human and guinea‐pig pulmonary tissues were investigated. In addition the receptor responsible for ET‐1‐induced prostanoid release in human bronchus was determined. 2 In human bronchus and human pulmonary artery ET‐1 (0.1 nm–0.3 μm) was a potent and effective contractile agent (pD2 = 7.58 ± 0.15, n = 6, and 8.48 ±0.11, n = 7, respectively). BQ‐123 (1–10 μm), a potent and selective ETA receptor antagonist, potently antagonized ET‐1‐induced contraction in human pulmonary artery (pKB = 6.8 with 1 μm BQ‐123, n = 7) but had no effect in human bronchus (n = 6). 3 Sarafotoxin S6c (0.1 nm–0.1 μm), the ETB‐selective agonist, did not contract human pulmonary artery (n = 5), but potently and effectively contracted human bronchus: pD2 = 8.41 ± 0.17, maximum response = 74.4 ± 3.1% of 10 μm carbachol; n = 5. BQ‐123 (1–10 μm) did not antagonize sarafotoxin S6c‐induced contraction in human bronchus (n = 5). 4 ET‐1 potently contracted guinea‐pig trachea, bronchus, pulmonary artery and aorta (pD2 = 8.15 ± 0.14, 7.72 ± 0.12, 8.52 ± 0.12, and 8.18 ± 0.12, respectively, n = 6–14). BQ‐123 (0.1–10 μm) antagonized ET‐1‐induced contractions in guinea‐pig pulmonary artery (pKB = 6.7 with 1 μm BQ‐123, n = 6), aorta (pKB = 7.1 with 1 μm BQ‐123, n = 6) and trachea (pKB = 6.2 with 1 μm BQ‐123, n = 6) but was without marked effect in bronchus (n = 4). In contrast, sarafotoxin S6c (0.1 nm–0.1 μm) did not contract guinea‐pig aorta (n = 4) or guinea‐pig pulmonary artery (n = 6) but potently and effectively contracted guinea‐pig bronchus: pD2 = 8.55 ± 0.1; maximum contraction = 63.6 ± 3.1% of 10 μm carbachol, n = 4. Sarafotoxin S6c (0.1 nm–0.1 μm) was a much less effective agonist in guinea‐pig trachea: maximum contraction = 13.9 ± 2.5% of 10 μm carbachol, n = 4; P < 0.0001, compared to bronchus. Contractions produced by sarafotoxin S6c in guinea‐pig bronchus or trachea were unaffected by BQ‐123 (10 μm, n = 4). 5 Significant differences were observed in the efficacy, relative to carbachol, but not the potency of sarafotoxin S6c in guinea‐pig airways, with a much greater maximum contractile response in bronchus (69.6 ± 2.4% of 10 μm carbachol, n = 6) or lower region of the trachea (48.5 ± 5.9% of 10 μm carbachol, n = 6) than in the middle region of the trachea (14.4 ± 4.0% of 10 μm carbachol, n = 6) or the upper region of the trachea (19.3 ± 2.7% of 10 μm carbachol, n = 6). There were minimal reg
ISSN:0007-1188
1476-5381
DOI:10.1111/j.1476-5381.1993.tb13938.x